Mar 28, 2021

ABBYY's new no-code AI technology could be a gamechanger

AI
RPA
Robotics
Revenue cycle management
Leila Hawkins
2 min
ABBYY's new no-code AI technology could be a gamechanger
ABBYY has launched a new no-code AI platform to help healthcare organisations speed up digital transformation...

Healthcare staff are now able to build their own AI-powered robots to help them deliver care to patients, thanks to new technology from software company ABBYY. 

Vantage 2 is a new low-code/no-code AI platform that enables healthcare staff to simply pick and choose the AI tools they require to help them with revenue cycle management, medical billing systems and other administrative applications.

The platform's AI tools can read, understand and root documents, with the necessary cognitive skills for RPA robots, automation systems, chatbots, and mobile solutions. 

The company has also launched ABBYY Marketplace, the first open marketplace for people to try and purchase reusable AI skills instead of having to undergo complex IT change management. It offers a large online collection of reusable technology assets including cognitive skills to classify documents and data. These pre-trained skills can be used for preregistration, referrals, invoices and discharge summaries. 

This has the potential to be a gamechanger for healthcare organisations - as it enables users to digitise their operations without having to rely on IT departments or need advanced IT skills. 

Built on microservices and packaged into containers by open-source system Kubernetes, its cloud-first architecture and low-code/no-code interface makes it easy to adopt AI and machine learning, key technologies to digitally transform an organisation. 

Kenya Smith, Solution Marketing Manager for Healthcare at ABBYY, explains how simplifying operations is crucial to post-pandemic recovery. “Analysis shows that the impact of the pandemic on the healthcare system will be felt for many years to come. Providers must find new ways to streamline operations and become more cost-effective, which involves accelerating digitalisation through both community and hospital workflows. 

"However, healthcare leaders are reluctant to undergo expensive IT transformation projects which underlines the importance of easy-to-use low-code AI platforms to quickly improve efficiencies" she said. 

ABBYY Vantage 2 is available now to early adopter customers and partners; NICE, Pegasystems and PwC are among the customers already integrating Vantage 2 with their platforms. 

Share article

Jun 18, 2021

Skin Analytics wins NHSX award for AI skin cancer tool 

AI
NHS
skincancer
Cancer
2 min
Skin Analytics uses AI to detect skin cancer and will be deployed across the NHS to ease patient backlogs

An artificial intelligence-driven tool that identifies skin cancers has received an award from NHSX, the NHS England and Department of Health and Social Care's initiative to bring technology into the UK's national health system. 

NHSX has granted the Artificial Intelligence in Health and Care Award to DERM, an AI solution that can identify 11 types of skin lesion. 

Developed by Skin Analytics, DERM analyses images of skin lesions using algorithms. Within primary care, Skin Analytics will be used as an additional tool to help doctors with their decision making. 

In secondary care, it enables AI telehealth hubs to support dermatologists with triage, directing patients to the right next step. This will help speed up diagnosis, and patients with benign skin lesions can be identified earlier, redirecting them away from dermatology departments that are at full capacity due to the COVID-19 backlog. 

Cancer Research has called the impact of the pandemic on cancer services "devastating", with a 42% drop in the number of people starting cancer treatment after screening. 

DERM is already in use at University Hospitals Birmingham and Mid and South Essex Health & Care Partnership, where it has led to a significant reduction in unnecessary referrals to hospital.

Now NHSX have granted it the Phase 4 AI in Health and Care Award, making DERM available to clinicians across the country. Overall this award makes £140 million available over four years to accelerate the use of artificial intelligence technologies which meet the aims of the NHS Long Term Plan.

Dr Lucy Thomas, Consultant Dermatologist at Chelsea & Westminster Hospital, said: “Skin Analytics’ receipt of this award is great news for the NHS and dermatology departments. It will allow us to gather real-world data to demonstrate the benefits of AI on patient pathways and workforce challenges. 

"Like many services, dermatology has severe backlogs due to the COVID-19 pandemic. This award couldn't have come at a better time to aid recovery and give us more time with the patients most in need of our help.”

Share article